AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31923303 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantoplasty
Number of subjects: 31
Study 31923303 — intervention group
Group type: COMPARATOR
Intervention: Glycine air polishing
Number of subjects: 31
Study 30914500 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (1.5 g DHA + 0.3 g EPA/day)
Number of subjects: 43
Study 29608336 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual task using the Kinect system
Number of subjects: 22
Study 29608336 — intervention group
Group type: COMPARATOR
Intervention: Real task (touching a real object)
Number of subjects: 22
Study 29608336 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual task
Number of subjects: 22
Study 29608336 — intervention group
Group type: COMPARATOR
Intervention: Real task
Number of subjects: 22
Study 26941086 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin alone
Number of subjects: 1430
Study 26941086 — intervention group
Group type: COMPARATOR
Intervention: Combination of rectal indomethacin and prophylactic pancreatic stent placement (PSP)
Number of subjects: 1430
Study 24571395 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol MDI with CPT
Number of subjects: 48
Study 24571395 — intervention group
Group type: COMPARATOR
Intervention: salbutamol MDI without CPT
Number of subjects: 48
Study 21327799 — intervention group
Group type: EXPERIMENTAL
Intervention: seT
Number of subjects: 32
Study 21327799 — intervention group
Group type: EXPERIMENTAL
Intervention: iCEM
Number of subjects: 32
Study 21327799 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SA
Number of subjects: 32
Study 19083105 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fat
Number of subjects: 366
Study 19083105 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat
Number of subjects: 366
Study 19083105 — intervention group
Group type: EXPERIMENTAL
Intervention: Available carbohydrates
Number of subjects: 366
Study 19083105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 366
Study 17805077 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 38
Study 17805077 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 15506067 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine 1 mg bid
Number of subjects: 15
Study 15506067 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 10865218 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg once a week (weekly alendronate group)
Number of subjects: 124
Study 10865218 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg daily (orally) for 1 month out of 3 (cyclical alendronate group)
Number of subjects: 124
Study 10865218 — intervention group
Group type: COMPARATOR
Intervention: Calcium/vitamin D supplements (control group)
Number of subjects: 124
Study 9124166 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 80 mg twice daily
Number of subjects: 0
Study 9124166 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 160 mg twice daily
Number of subjects: 0
Study 9124166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8228077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg b.i.d.)
Number of subjects: 10
Study 8228077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.i.d.)
Number of subjects: 10
Study 8228077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8228077 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-antagonist (single dose)
Number of subjects: 10
Study 8228077 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-antagonist (14-day chronic dosing)
Number of subjects: 10
Study 8228077 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-antagonist (28-day chronic dosing)
Number of subjects: 10
Study 3536469 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (1.0 g twice daily for patients ≤ 65 kg; 1.5 g twice daily for patients > 65 kg)
Number of subjects: 20
Study 3536469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3042009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol + UVB therapy (27 patients)
Number of subjects: 53
Study 3042009 — intervention group
Group type: COMPARATOR
Intervention: Dithranol only (21 patients)
Number of subjects: 53
Study 3042009 — intervention group
Group type: COMPARATOR
Intervention: Dithranol only (16 patients who cleared)
Number of subjects: 53
Study 30667588 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Management Intervention (WMI)
Number of subjects: 43
Study 30667588 — intervention group
Group type: COMPARATOR
Intervention: Control group (Cardiac Rehabilitation alone)
Number of subjects: 43
Study 28302275 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D vision laparoscopic simulator training
Number of subjects: 34
Study 28302275 — intervention group
Group type: COMPARATOR
Intervention: 2D vision laparoscopic simulator training
Number of subjects: 34
Study 28302275 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention test under 2D conditions after 3D training
Number of subjects: 34
Study 28302275 — intervention group
Group type: COMPARATOR
Intervention: Retention test under 2D conditions after 2D training
Number of subjects: 34
Study 26471852 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching and strengthening exercises plus manual therapy
Number of subjects: 46
Study 26471852 — intervention group
Group type: COMPARATOR
Intervention: Stretching and strengthening exercises alone
Number of subjects: 46
Study 26471852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (exercise alone and exercise plus manual therapy)
Number of subjects: 46
Study 23834545 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg kg(‐1))
Number of subjects: 11
Study 23834545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 21660778 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 paced chapters
Number of subjects: 28
Study 21660778 — intervention group
Group type: COMPARATOR
Intervention: One book with 10 chapters
Number of subjects: 28
Study 18669012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWHs)
Number of subjects: 0
Study 18669012 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 18669012 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirically adjusted doses of LMWH
Number of subjects: 0
Study 18669012 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 16679545 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/d sodium selenite in addition to chemotherapy
Number of subjects: 30
Study 16679545 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 30
Study 12780888 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diltiazem (2%) ointment
Number of subjects: 43
Study 12780888 — intervention group
Group type: COMPARATOR
Intervention: Glyceryltrinitrate (GTN) (0.5%) ointment
Number of subjects: 43
Study 10840128 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive oddball task with labial /ba/‐dental /da/ contrasts
Number of subjects: 0
Study 10840128 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive oddball task with Hindi dental /da/‐retroflex /da/ contrasts
Number of subjects: 0
Study 10840128 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive oddball task with within‐category (two /ba/ tokens) contrasts
Number of subjects: 0
Study 9221182 — intervention group
Group type: EXPERIMENTAL
Intervention: Consupren at an initial dose of 5 mg/kg/d (CS group, n = 16)
Number of subjects: 30
Study 9221182 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide at a dose of 1.5 mg/kg/d (K group, n = 11)
Number of subjects: 30
Study 9221182 — intervention group
Group type: EXPERIMENTAL
Intervention: Consupren (CS group)
Number of subjects: 30
Study 9221182 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (K group)
Number of subjects: 30
Study 1587713 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mg all‐rac‐alpha‐tocopherol acetate/kg/d intravenously for 5 days
Number of subjects: 0
Study 1587713 — intervention group
Group type: COMPARATOR
Intervention: Control group received the same fat emulsions without supplemented vitamin E
Number of subjects: 0
Study 2933186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (STK)
Number of subjects: 67
Study 2933186 — intervention group
Group type: EXPERIMENTAL
Intervention: STK and coronary bypass surgery within 24 hr
Number of subjects: 67
Study 2933186 — intervention group
Group type: COMPARATOR
Intervention: No successful reperfusion with STK
Number of subjects: 67
Study 2933186 — intervention group
Group type: EXPERIMENTAL
Intervention: STK treatment within 2 hr of onset
Number of subjects: 67
Study 2933186 — intervention group
Group type: EXPERIMENTAL
Intervention: STK treatment after 2 hr of onset
Number of subjects: 67
Study 2933186 — intervention group
Group type: EXPERIMENTAL
Intervention: Successfully reperfused patients
Number of subjects: 67
Study 2933186 — intervention group
Group type: COMPARATOR
Intervention: Partial reperfusion
Number of subjects: 67
Study 2933186 — intervention group
Group type: COMPARATOR
Intervention: Failed reperfusion
Number of subjects: 67
Study 30133507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue content of total 18:1t (quintiles 5 versus 1)
Number of subjects: 3156
Study 30133507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue content of 18:1 Δ6‐10t (quintiles 5 versus 1)
Number of subjects: 3156
Study 30133507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue content of 18:1 Δ11t (quintiles 5 versus 1)
Number of subjects: 3156
Study 30133507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue content of 18:2 Δ9c, 11t
Number of subjects: 3156
Study 27161257 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg, three times daily)
Number of subjects: 123
Study 27161257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 24878421 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cough challenge at days 0 and 1
Number of subjects: 42
Study 24878421 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cough challenge at days 2 and 3
Number of subjects: 42
Study 24878421 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cough challenge at days 4 and 5
Number of subjects: 42
Study 24878421 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy baseline measurement (recovery) 4-8 weeks post-viral infection
Number of subjects: 42
Study 23107220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin 40 IU q.i.d. (n = 34)
Number of subjects: 62
Study 23107220 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 28)
Number of subjects: 62
Study 20654060 — intervention group
Group type: EXPERIMENTAL
Intervention: Akreos AO aberration-free aspheric IOL
Number of subjects: 130
Study 20654060 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOL (KS-1, Cannon Staar)
Number of subjects: 130
Study 17445333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m2 weekly
Number of subjects: 72
Study 17445333 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine 6 mg/m2 weekly
Number of subjects: 72
Study 15729485 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin sodium (IPM/CS) plus betamethasone
Number of subjects: 100
Study 15729485 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IPM/CS or betamethasone)
Number of subjects: 100
Study 12729866 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication (drug trial)
Number of subjects: 714
Study 12729866 — intervention group
Group type: COMPARATOR
Intervention: Epidemiological study (control)
Number of subjects: 714
Study 10629368 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor using oral prostaglandin E(2) at 37 weeks
Number of subjects: 36
Study 10629368 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 36
Study 10629368 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 36
Study 9183091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received a sheet illustrating eight positive aspects of breast feeding and a questionnaire on breast feeding at 36 weeks antenatal visit.
Number of subjects: 193
Study 9183091 — intervention group
Group type: COMPARATOR
Intervention: Control group received routine antenatal care.
Number of subjects: 193
Study 7902966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2 out of 3 partial autonomic blockers (indoramin, propranolol, atropine)
Number of subjects: 48
Study 7902966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3710284 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc aspartate application during pregnancy
Number of subjects: 524
Study 3710284 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc application)
Number of subjects: 524
Study 31296044 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic release (ER)
Number of subjects: 60
Study 31296044 — intervention group
Group type: COMPARATOR
Intervention: In situ open neurolysis (OR)
Number of subjects: 60
Study 30483715 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment
Number of subjects: 78
Study 30483715 — intervention group
Group type: COMPARATOR
Intervention: Conventional root canal preparation and calcium hydroxide sealant (Control)
Number of subjects: 78
Study 28730888 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation group (moderate endurance and resistance training plus breathing exercises, 3-5 times per week)
Number of subjects: 40
Study 28730888 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation group
Number of subjects: 40
Study 28730888 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 26065986 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 16490
Study 26065986 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate 110 mg
Number of subjects: 16490
Study 26065986 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate 150 mg
Number of subjects: 16490
Study 24035168 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin-ER (extended-release niacin) at a maximum of 1,500 mg/day for 12 weeks
Number of subjects: 27
Study 24035168 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 24035168 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin-ER
Number of subjects: 27
Study 24035168 — intervention group
Group type: COMPARATOR
Intervention: niacin-ER and placebo
Number of subjects: 27
Study 21764404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral prevention program
Number of subjects: 71
Study 21764404 — intervention group
Group type: COMPARATOR
Intervention: Credible control program
Number of subjects: 71
Study 18783622 — intervention group
Group type: EXPERIMENTAL
Intervention: RTEC with nutrition education
Number of subjects: 147
Study 18783622 — intervention group
Group type: COMPARATOR
Intervention: RTEC alone (1 or 2 doses)
Number of subjects: 147
Study 18783622 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 147
Study 16644439 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Contrast Echocardiography (MCE)
Number of subjects: 72
Study 16644439 — intervention group
Group type: COMPARATOR
Intervention: Single Photon Emission Computed Tomography (SPECT)
Number of subjects: 72
Study 12553385 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia (CSA) with prilocaine 2% 40 mg
Number of subjects: 30
Study 12553385 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural anaesthesia (CEA) with prilocaine 1% 150 mg
Number of subjects: 30
Study 10376170 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine in patients
Number of subjects: 460
Study 10376170 — intervention group
Group type: EXPERIMENTAL
Intervention: Active migraine in patients
Number of subjects: 460
Study 10376170 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased migraine in patients
Number of subjects: 460
Study 10376170 — intervention group
Group type: COMPARATOR
Intervention: Ceased migraine in controls
Number of subjects: 460
Study 10376170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular pain in patients with migraine
Number of subjects: 460
Study 8694727 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% rimexolone
Number of subjects: 40
Study 8694727 — intervention group
Group type: COMPARATOR
Intervention: 0.1% fluorometholone
Number of subjects: 40
Study 8694727 — intervention group
Group type: COMPARATOR
Intervention: 0.1% dexamethasone sodium phosphate
Number of subjects: 40
Study 8694727 — intervention group
Group type: COMPARATOR
Intervention: 1.0% prednisolone acetate
Number of subjects: 40
Study 1910799 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 75 microgram/kg
Number of subjects: 100
Study 1910799 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 20 microgram/kg
Number of subjects: 100
Study 1910799 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100
Study 7049341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 22
Study 7049341 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil
Number of subjects: 22
Study 7049341 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 22
Study 7049341 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Friedreich's Ataxia
Number of subjects: 22
Study 31393676 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D vision
Number of subjects: 60
Study 31393676 — intervention group
Group type: COMPARATOR
Intervention: 2D vision
Number of subjects: 60
Study 31537777 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation therapy
Number of subjects: 42
Study 31537777 — intervention group
Group type: COMPARATOR
Intervention: Control group (persistent monitoring)
Number of subjects: 42
Study 28705206 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyrax-type expander anchored to permanent teeth
Number of subjects: 44
Study 28705206 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Hyrax-type expander anchored to deciduous teeth
Number of subjects: 44
Study 28705206 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Haas-type expander anchored to deciduous teeth
Number of subjects: 44
Study 26509683 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LITUS (n = 20) at a frequency of 3 MHz and an energy intensity of 0.132 W/cm² continuously for 3 hours using 1 transducer
Number of subjects: 26
Study 26509683 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LITUS (n = 20) at a frequency of 3 MHz and an energy intensity of 0.132 W/cm² continuously for 3 hours using 2 transducers
Number of subjects: 26
Study 26509683 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LITUS (n = 20)
Number of subjects: 26
Study 26509683 — intervention group
Group type: COMPARATOR
Intervention: Placebo LITUS (n = 6)
Number of subjects: 26
Study 23838771 — intervention group
Group type: COMPARATOR
Intervention: Single Vision Lenses (SVLs)
Number of subjects: 84
Study 23838771 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses (PALs)
Number of subjects: 84
Study 22559158 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 and cisplatin (SP)
Number of subjects: 96
Study 22559158 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine and cisplatin (GP)
Number of subjects: 96
Study 19177536 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based exercise program
Number of subjects: 102
Study 19177536 — intervention group
Group type: COMPARATOR
Intervention: Water-based exercise program
Number of subjects: 102
Study 18057477 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytomenadione (vitamin K1), 1 mg intramuscularly
Number of subjects: 170
Study 18057477 — intervention group
Group type: COMPARATOR
Intervention: Menadione (vitamin K3), 1 mg intramuscularly
Number of subjects: 170
Study 11239326 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic contoured cushion
Number of subjects: 9
Study 11239326 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat foam cushion
Number of subjects: 9
Study 9602575 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. morphine, i.m. diclofenac and intercostal nerve blocks from T2 to T11, 20 min before operation
Number of subjects: 30
Study 9602575 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections before operation, and i.v. morphine, i.m. diclofenac and intercostal nerve blocks from T2 to T11 at the end of surgery
Number of subjects: 30
Study 7767541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, four times daily for 16 weeks)
Number of subjects: 38
Study 7767541 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (200 micrograms, four times daily for 16 weeks)
Number of subjects: 38
Study 7767541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 2123142 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition with 15 or 30 kcal/kg.day and 0.30 g of N with standard or branch-chain (BC) enriched AA solutions
Number of subjects: 0
Study 2123142 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition with 30 kcal/kg.day
Number of subjects: 0
Study 2123142 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-enriched AA solutions
Number of subjects: 0
Study 508132 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study 31855097 — intervention group
Group type: EXPERIMENTAL
Intervention: Online community support and information sharing regarding stress urinary incontinence management.
Number of subjects: 762
Study 31855097 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of risk factors, prevention strategies, and treatment recommendations.
Number of subjects: 762
Study 30936584 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow Awareness Technology (Group A)
Number of subjects: 33
Study 30936584 — intervention group
Group type: EXPERIMENTAL
Intervention: Level Detector (Group B)
Number of subjects: 33
Study 30936584 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 33
Study 28549081 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision videolaryngoscope (KVL)
Number of subjects: 200